期刊文献+

替米沙坦、非洛地平联合二甲双胍治疗高血压合并糖尿病36例 被引量:2

下载PDF
导出
摘要 目的观察替米沙坦、非洛地平缓释片联合二甲双胍治疗高血压合并2型糖尿病的疗效。方法将体检时发现的高血压合并2型糖尿病患者72例随机均分成两组,对照组36例给予非洛地平缓释片5mg,二甲双胍缓释片1.5g,均1次/d;治疗组36例在对照组治疗的基础上加服替米沙坦片40mg,1次/d。两组均以12周为1个疗程,1个疗程结束后观察各组的降压、降糖效果。结果治疗后对照组血压为(143±16)/(89±10)mmHg,空腹血糖(FPG)为(7.5±2.1)mmol/L,餐后2小时血糖(2hPG)为(12.1±4.2)mmol/L;治疗组血压为(125±14)/(75±11)mmHg,FPG为(6.5±2.2)mmol/L,2hPG为(10.9±3.9)mmol/L。两组的降压、降糖疗效有显著性差异(P<0.05)。结论替米沙坦、非洛地平缓释片联合二甲双胍治疗高血压合并2型糖尿病疗效确切,服药方便。
出处 《中国药业》 CAS 2010年第11期53-54,共2页 China Pharmaceuticals
  • 相关文献

参考文献2

二级参考文献9

  • 1Yamagishi S, Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR -gamma2 - inducing property. Med Hypotheses ,2005,64.
  • 2Landsberg L. Insulin sensitivity in the pathogensis of hypeaension and hypertensive complication. Clin Exp Hypertens, 1996,18 (3) :337 - 338.
  • 3Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as aunique angiotensin receptor antagonist with selective PPARv2 modulating activityl Hypertension, 2004,43:993 - 1002.
  • 4Kana A, TakayukiM, Isao K, et al. Telmisartan prevents obesity and increases theexpression of uncoupling protein in diet -induced obese mice. Hypertention, 2006,48: 51.
  • 5Ralfa B, TanjaR,Daniel A, et al. Telmisartan improves insuline sensitivity innondiabetic patients with essential hypertension. Metabol Clin Experim, 2006, 155:1159.
  • 6Benson SC,Pershadsingh HA,Ho CI,et al.Identification of telmisar tanas a unique angiotensinⅡreceptor antagonist with selective PPARγ-modulating activity[].Journal of Hypertension.2004
  • 7Amer P.Free fatty acids——do they play a central role in type2dia-betes?[].Diabetes Obesity and Metabolism.2001
  • 8Theuma P,Fonseca VA.Inflammation,insulinresistence and atherosclero-sis[].Metabolic Syndrome and It’s Rrlated Disorders.2004
  • 9Lithell HO.Effects of antihypertensive drugs on insulin,glucose and lipid metabolism[].Diabetes Care.1991

共引文献13

同被引文献13

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部